Europe Ophthalmology Drug and Device Market Size (2024 - 2029)

The European ophthalmic drugs and devices market is anticipated to experience growth driven by an increasing prevalence of eye diseases and advancements in technology. The market's expansion is influenced by the rising demand for treatments and surgeries, particularly as services resume post-pandemic. Technological innovations in ophthalmic devices, such as new intraocular lens products, are contributing to this growth. However, challenges such as the high risk associated with eye surgeries and stringent regulatory requirements may pose constraints on the market's expansion.

Market Size of Europe Ophthalmology Drug and Device Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Europe Ophthalmology Drug and Device Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2021 - 2022
CAGR 5.30 %
Market Concentration Medium

Major Players

Europe Ophthalmology Drug and Device Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Europe Ophthalmic Drugs and Devices Market Analysis

The European ophthalmology drug and device market is expected to register a CAGR of 5.3% over the forecast period.

COVID-19 has affected the world and has had a significant impact on the healthcare system. The COVID-19 outbreak has resulted in many changes in European healthcare practice, especially ophthalmology drugs and devices in Europe majorly impacted. The elective operations/therapies and non-emergency medical procedures had nearly halted in most medical centers, and these services witnessed a significant decline, including cataract and vitreoretinal surgeries. An article by the European Journal of Ophthalmology published in March 2021 reported that the epidemic severely struck ophthalmic surgical procedures in Italy and other European countries. The article also reported that eye surgical procedures were limited to urgent procedures and intravitreal injections in all centers due to government rules. Thus, although an overall reduction in elective, urgent, and intravitreal injection procedures was observed during the lockdown period in the European countries, however after a post-pandemic, the market witnessed significant growth as these services got resumed.

The growth of the market is driven by the factors such as the growing prevalence of eye disease, technological advancements in the field of ophthalmology, and the rising geriatric population. The growing prevalence of eye disease in Europe is driving the market. For instance, according to a study published in the European Journal of Opthalmology in March 2021, an article reported that myopia is predicted to become the most common cause of irreversible vision impairment and blindness in Europe. Similarly, as per the article published in the Journal of Glaucoma in August 2022 reported that primary open-angle glaucoma is a neurodegenerative disease highly prevalent in the European adult population, with cases expected to increase over the aging population is expected to increase in European countries. Thus, a high incidence of eye disorders is increasing the demand for medicines and related surgeries, which is expected to boost market growth over the forecast period.

The technological advancement in ophthalmic devices in Europe is also driving the market. For instance, in September 2022, BVI received the certification for its intraocular lens (IOL) portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its notified body, the British Standards Institution (BSI). The new regulatory criteria came into effect in May 2021, replacing the prior Medical Device Directive (MDD). Additionally, in September 2022, SIFI launched Evolux, a novel extended monofocal intraocular lens (IOL) based on a hydrophobic material and a non-diffractive profile designed to provide better intermediate vision. Evolux was developed on a patented technology platform, pioneering the extension of the depth of focus through wavefront engineering. Thus, such product development and launches in Europe are expected to drive market growth.

Thus, all factors mentioned above, such as the rising prevalence of ophthalmic diseases and technological advancement in ophthalmology devices, are expected to boost the market over the forecast period. However, the high risk associated with eye surgery and stringent regulations may restrain the market growth over the forecast period.

Europe Ophthalmic Drugs and Devices Industry Segmentation

As per the scope of the report, ophthalmic drugs are administered to the eyes, most typically as an eye drop formulation. These topical formulations are used to combat a multitude of diseased states of the eye and ophthalmic devices are medical equipment designed for diagnosis, surgery, and vision correction. These devices gain increased importance and adoption due to the high prevalence of various ophthalmic diseases such as glaucoma, cataract, and other vision-related issues. The Europe Ophthalmology Drug and Devices Market is Segmented by Product (Devices (Surgical Devices (Intraocular Lenses, Ophthalmic Lasers, Other Surgical Devices), Diagnostic Devices), Drugs (Glaucoma Drugs, Retinal Disorder Drugs, Dry Eye Drugs, Allergic Conjunctivitis, and Inflammation Drugs, and Other Drugs)), Disease (Glaucoma, Cataract, Age-related Macular Degeneration, Inflammatory Diseases, Refractive Disorders, and Other Diseases) and Geography (Germany, United Kingdom, France, Italy, Spain and the Rest of Europe). The report offers the value (in USD million) for the above segments.

By Product Type
Devices
Surgical Devices
Intraocular Lenses
Ophthalmic Lasers
Other Surgical Devices
Diagnostic Devices
Drugs
Glaucoma Drugs
Retinal Disorder Drugs
Dry Eye Drugs
Allergic Conjunctivitis and Inflammation Drugs
Other Drugs
By Disease
Glaucoma
Cataract
Age-related Macular Degeneration
Inflammatory Diseases
Refractive Disorders
Other Diseases
Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region Or Segment?
Customize Now

Europe Ophthalmology Drug and Device Market Size Summary

The European ophthalmic drugs and devices market is poised for growth, driven by an increasing prevalence of eye diseases, technological advancements, and a rising geriatric population. The market experienced disruptions due to the COVID-19 pandemic, which led to a significant decline in elective and non-emergency procedures. However, post-pandemic recovery has seen a resurgence in demand for ophthalmic services. The growing incidence of conditions such as myopia and glaucoma, coupled with advancements in ophthalmic technologies, is expected to propel market expansion. Innovations like the certification of intraocular lens portfolios and the launch of novel lenses are indicative of the sector's dynamic nature, contributing to the market's positive outlook.

Germany is anticipated to be a key growth driver within the region, fueled by its aging population and the prevalence of eye-related disorders. The country's market growth is supported by technological advancements in ophthalmic devices and an increasing number of vision correction surgeries. The fragmented nature of the market, with both international and local players, adds to the competitive landscape. Notable companies such as Alcon Inc., Bausch Health Companies Inc., and Carl Zeiss Meditec AG are significant contributors to the market. Recent regulatory approvals for new treatments further underscore the market's potential, with products like Roche's Vabysmo and the biosimilar Ranivisio gaining traction.

Explore More

Europe Ophthalmology Drug and Device Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Prevalence of Eye Disease

      2. 1.2.2 Technological Advancements in the Field of Ophthalmology

      3. 1.2.3 Rising Geriatric Population

    3. 1.3 Market Restraints

      1. 1.3.1 High Risk Associated with Eye Surgery

      2. 1.3.2 Stringent Regulations

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Product Type

      1. 2.1.1 Devices

        1. 2.1.1.1 Surgical Devices

          1. 2.1.1.1.1 Intraocular Lenses

          2. 2.1.1.1.2 Ophthalmic Lasers

          3. 2.1.1.1.3 Other Surgical Devices

        2. 2.1.1.2 Diagnostic Devices

      2. 2.1.2 Drugs

        1. 2.1.2.1 Glaucoma Drugs

        2. 2.1.2.2 Retinal Disorder Drugs

        3. 2.1.2.3 Dry Eye Drugs

        4. 2.1.2.4 Allergic Conjunctivitis and Inflammation Drugs

        5. 2.1.2.5 Other Drugs

    2. 2.2 By Disease

      1. 2.2.1 Glaucoma

      2. 2.2.2 Cataract

      3. 2.2.3 Age-related Macular Degeneration

      4. 2.2.4 Inflammatory Diseases

      5. 2.2.5 Refractive Disorders

      6. 2.2.6 Other Diseases

    3. 2.3 Geography

      1. 2.3.1 Germany

      2. 2.3.2 United Kingdom

      3. 2.3.3 France

      4. 2.3.4 Italy

      5. 2.3.5 Spain

      6. 2.3.6 Rest of Europe

Europe Ophthalmology Drug and Device Market Size FAQs

The Europe Ophthalmology Drug and Device Market is projected to register a CAGR of 5.30% during the forecast period (2024-2029)

Topcon Corporation, Johnson & Johnson, Carl Zeiss Meditec AG, Pfizer and Nidek Co. Ltd are the major companies operating in the Europe Ophthalmology Drug and Device Market.

Europe Ophthalmic Drugs & Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)